TearCare clearance, corneal crosslinking lead cornea news in December
Click Here to Manage Email Alerts
An FDA clearance and dry eye disease trials led cornea coverage from December.
Read the best-performing pieces of cornea coverage from December below.
FDA clears TearCare system for treatment of meibomian gland dysfunction
The TearCare system has received 510(k) clearance from the FDA for the treatment of meibomian gland dysfunction, according to a press release from Sight Sciences. Read more.
VIDEO: Cross-linking ‘one of the most disruptive’ procedures in ophthalmology
NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, Eric D. Donnenfeld, MD, discusses the benefits and applications of corneal cross-linking in patients with keratoconus. Watch more.
Endpoint achieved in phase 2 trial of OTX-DED for short-term dry eye disease treatment
OTX-DED met the primary endpoint in a phase 2 trial investigating the ophthalmic insert for safety and efficacy in the short-term treatment of dry eye disease, according to a press release from Ocular Therapeutix. Read more.
Meibomian gland dysfunction and dry eye: The state of diagnosis and treatment today
With the exception of the eventual, however begrudging, acceptance of dry eye disease as a thing, the biggest paradigm shift in the dry eye world has been the acknowledgement that both tear quality and quantity matter. Read more.
SARS-CoV-2 beta variant replicates better, induces higher immune response in conjunctiva
A study conducted on tissue samples and cultured cells demonstrated that SARS-CoV-2 can efficiently infect human conjunctival epithelial cells, eliciting innate immune response. Read more.
Collapse
Read more about
Click Here to Manage Email Alerts